Candel Therapeutics, Inc. Common Stock CADL
Analyst Ratings
- Consensus
- Buy — 7 Buy · 1 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $19.86 (+51.2% upside)
Key Stats
- Today's Range
- $12.38 – $13.26
- 50-Day Range
- $7.93 – $13.82
- 52-Week Range
- $4.35 – $13.82
- Volume
- 1.34 million shs
- Average Volume
- 1.30 million shs
- Market Cap
- $1.00 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 7.97
- Price / Sales
- —
Short Interest
- Short Interest
- 0.04%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-88,531,000
- Net Margin
- —
- Return on Equity
- -70.19%
- Debt-to-Equity
- —
About Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Related Stocks
Compare head-to-head: CADL vs AMGN·CADL vs MRNA·CADL vs HALO·CADL vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.